Table 1.
Demographics and baseline characteristics
| Degarelix (n=275) |
Leuprolide (n=269) |
Total (N=544) |
|
|---|---|---|---|
| Age, mean (SD), yrs | 73.3 (7.28) | 73.1 (7.16) | 73.2 (7.22) |
| Race, no. (%) | |||
| American Indian or Alaska Native | 2 (0.7) | 2 (0.4) | |
| Asian | 3 (1.1) | 5 (1.9) | 8 (1.5) |
| Black or African American | 16 (5.9) | 12 (4.5) | 28 (5.2) |
| White | 252 (91.6) | 251 (93.3) | 503 (93.0) |
| All | 273 (100.0) | 268 (100.0) | 541 (100.0) |
| Ethnicity, no. (%) | |||
| Hispanic or Latino | 16 (5.9) | 14 (5.2) | 30 (5.6) |
| Not Hispanic or Latino | 256 (94.1) | 254 (94.8) | 510 (94.4) |
| All | 272 (100.0) | 268 (100.0) | 540 (100.0) |
| Weight, mean, kg | 86.01 | 87.10 | 86.55 |
| BMI, no./No. | 273/275 | 268/269 | 541/544 |
| Mean, kg/m2 | 28.38 | 28.58 | 28.48 |
| Smoking status, no. (%) | |||
| Current | 34 (12.4) | 48 (17.8) | 82 (15.1) |
| Former | 104 (37.8) | 107 (39.8) | 211 (38.8) |
| Never | 73 (26.5) | 68 (25.3) | 141 (25.9) |
| Baseline BP (diastolic >90 or systolic >140 mm Hg), no. (%) | 94 (34.2) | 90 (33.5) | 184 (33.8) |
| Total serum cholesterol, mean (SD), mmol/L | 4.1 (1.09) | 4.2 (1.09) | 4.1 (1.09) |
| Type 2 diabetes mellitus, no. (%) | 88 (32.0) | 87 (32.3) | 175 (32.2) |
| NT-proBNP, no./No. | 266/275 | 263/269 | 529/544 |
| Mean (SD), pg/mL | 665.4 (1552) | 675.0 (3154) | 670.2 (2479) |
| High sensitivity C-reactive protein, no./No. | 270/275 | 264/269 | 534/544 |
| Mean (SD), mg/dL | 0.6896 (1.825) | 0.5707 (1.747) | 0.6308 (1.786) |
| Troponin T, no./No. | 267/275 | 257/269 | 524/544 |
| Mean (SD), pg/mL | 18.79 (17.78) | 17.62 (17.66) | 18.21 (17.71) |
| Prostate cancer therapy history, no. (%) | |||
| Radiotherapy | 42 (15.3) | 31 (11.5) | 73 (13.4) |
| Radical prostatectomy | 37 (13.5) | 27 (10.0) | 64 (11.8) |
| Hormonal therapy | 21 (7.6) | 23 (8.6) | 44 (8.1) |
| Other | 13 (4.7) | 11 (4.1) | 24 (4.4) |
| Gleason score | |||
| 2–4 | 1 (0.4) | 2 (0.7) | 3 (0.6) |
| 5–6 | 34 (12.4) | 33 (12.3) | 67 (12.3) |
| 7–10 | 238 (86.5) | 234 (87.0) | 472 (86.8) |
| Stage of prostate cancer, no. (%) | |||
| Localised | 138 (50.2) | 133 (49.4) | 271 (49.8) |
| Locally advanced | 63 (22.9) | 80 (29.7) | 143 (26.3) |
| Metastatic | 63 (22.9) | 48 (17.8) | 111 (20.4) |
| Not classifiable | 11 (4.0) | 8 (3.0) | 19 (3.5) |
| Testosterone, no./No. | 274/275 | 269/269 | 543/544 |
| Median (25th, 75th), ng/dL | 325.5 (252, 416) | 338.0 (249, 415) | 330.0 (250, 416) |
| Prostate specific antigen, no./No. | 275/275 | 268/269 | 543/544 |
| Median (25th, 75th), ng/mL | 13.4 (5.9, 34.5) | 12.7 (5.8, 29.8) | 12.8 (5.8, 32.7) |
| Myocardial infarction | 127 (46.2%) | 125 (46.5%) | 252 (46.3%) |
| Coronary carotid, or iliofemoral revascularization | 199 (72.4%) | 194 (72.1%) | 393 (72.2%) |
| Coronary, carotid, or iliofemoral stenosis >50% by angiography | 108 (39.3%) | 120 (44.6%) | 228 (41.9%) |
| Carotid stenosis >50% by ultrasound | 19 (6.9%) | 16 (5.9%) | 35 (6.4%) |
| Ankle-brachial index <0.9 | 34 (12.4%) | 41 (15.2%) | 75 (13.8 %) |
| Atrial fibrillation | 55 (20.0) | 47 (17.5) | 102 (18.8) |
| Dyslipidemia, no. (%) | 106 (38.5) | 91 (33.8) | 197 (36.2) |
| Hypertension, no. (%) | 232 (84.4) | 235 (87.4) | 467 (85.8) |
| Concomitant medications, no. (%) | |||
| Cardiovascular medications | 268 (97.5) | 262 (97.4) | 530 (97.4) |
| Lipid modifying agents | 234 (85.1) | 224 (83.3) | 458 (84.2) |
| Agents acting on the renin-angiotensin system | 202 (73.5) | 194 (72.1) | 396 (72.8) |
| Beta blockers | 194 (70.5) | 180 (66.9) | 374 (68.8) |
BMI indicates body mass index; NT-proBNP, N-terminal pro-hormone B-type natriuretic peptide; SD, standard deviation.